IL-17 and limits of success.

Autor: Omidian Z; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States., Ahmed R; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States., Giwa A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States., Donner T; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States., Hamad ARA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States. Electronic address: ahamad@jhmi.edu.
Jazyk: angličtina
Zdroj: Cellular immunology [Cell Immunol] 2019 May; Vol. 339, pp. 33-40. Date of Electronic Publication: 2018 Sep 17.
DOI: 10.1016/j.cellimm.2018.09.001
Abstrakt: Interleukin-17 (IL-17) is a potent proinflammatory cytokine that protects a host against fungal and extracellular bacterial infections. On the other hand, excessive or dysregulated production of IL-17 underlines susceptibility to autoimmune disease. Consequently, blocking IL-17 has become an effective strategy for modulating several autoimmune diseases, including multiple sclerosis (MS), psoriasis, and rheumatoid arthritis (RA). Notably, however, IL-17 blockade remains ineffective or even pathogenic against important autoimmune diseases such as inflammatory bowel disease (IBD). Furthermore, the efficacy of IL-17 blockade against other autoimmune diseases, including type 1 diabetes (T1D) is currently unknown and waiting results of ongoing clinical trials. Coming years will determine whether the efficacy of IL-17 blockade is limited to certain autoimmune diseases or can be expanded to other autoimmune diseases. These efforts include new clinical trials aimed at testing second-generation agents with the goal of increasing the efficiency, spectrum, and ameliorating side effects of IL-17 blockade. Here we briefly review the roles of IL-17 in the pathogenesis of selected autoimmune diseases and provide updates on ongoing and recently completed trials of IL-17 based immunotherapies.
(Copyright © 2018. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: